Adding elotuzumab to standard treatment for myeloma reduced disease progression

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints. The two-year progression-free survival rate was 41% in the elotuzumab group versus 27% in the control group.

Presented by Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, at the 20th Congress of the European Hematology Association (EHA).